Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$81.60 USD

81.60
4,618,519

+0.23 (0.28%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Align Technology Stock Dips on Macroeconomic Issues, FX Headwind

ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.

COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD

Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.

Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?

Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.

Reasons to Retain Revvity Stock in Your Portfolio for Now

RVTY's strong product portfolio raises optimism about the stock.

Boston Scientific (BSX) Dips More Than Broader Market: What You Should Know

In the latest trading session, Boston Scientific (BSX) closed at $81.37, marking a -0.72% move from the previous day.

QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping

QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.

Should You Continue to Retain ABT Stock in Your Portfolio Now?

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

Butterfly Network's Stock Surges on iQ3 Device Launch in Europe

Shares of BFLY gain almost 27% following the announcement of the launch of its latest handheld ultrasound device, Butterfly iQ3, in Europe.

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.

Reasons to Retain STERIS Stock in Your Portfolio for Now

STE's strong prospects in the healthcare business arm bode well for investors.

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump

EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.

Should You Consider Retaining ZBH Stock in Your Portfolio Now?

Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.

Should You Continue to Retain PODD Stock in Your Portfolio Now?

Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

QDEL's strong product portfolio raises optimism about the stock.

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.

Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now

Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock

AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.

Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Boston Scientific (BSX) closed at $81.79, indicating a +1.39% shift from the previous trading day.

Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131

CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.

Should You Consider Retaining Bruker Stock in Your Portfolio Now?

BRKR's robust growth potential across its major segments is encouraging. Yet, macro woes and competitive pressure can pose challenges.

Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up

CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.